Novartis AG (NVS) is a publicly traded Healthcare sector company. As of May 20, 2026, NVS trades at $151.00 with a market cap of $284.59B and a P/E ratio of 0.00. NVS moved -0.01% today. Year to date, NVS is +8.59%; over the trailing twelve months it is +35.89%. Its 52-week range spans $96.06 to $170.46. Analyst consensus is buy with an average price target of $167.22. Rallies surfaces NVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Novartis Partners on Brain Transporter Tech as Leqembi Sales Expected at $900M: BioArctic's Q1 report showed EUR500m in partner-driven sales and SEK2bn cash reserves, funding R&D for its brain transporter platform. It established a partnership with Novartis on brain transporter technology and projects Leqembi sales above USD900m in 2026, offering upside to Novartis’ Alzheimer’s pipeline.
| Metric | Value |
|---|---|
| Price | $151.00 |
| Market Cap | $284.59B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 4.74% |
| 52-Week High | $170.46 |
| 52-Week Low | $96.06 |
| Volume | 1.11M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover NVS: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $167.22.